Shanghai Henlius Biotech Inc. has licensed its adalimumab biosimilar Handayuan to Getz Pharma Pvt. Ltd. and its affiliated company Getz Pharma International FZ LLC in an $8 million deal.
Biocon Ltd. said its subsidiary Biocon Biologics Ltd. has agreed to buy out partner Viatris Inc., bringing aboard the latter’s biosimilars business, for $3.34 billion, including cash of $2.34 billion and compulsorily convertible preference shares (CCPS) in BBL, valued at $1 billion.
Even as China sees strong and continuous growth in patent applications from its medical technology industry, regulators are imposing stricter regulations to curb what they see as "abnormal applications." China’s medical technology sector saw year-on-year growth of 28.7% in 2021 for valid invention patents, according to data from the China National Intellectual Property Administration.
Shanghai Henlius Biotech Inc. has licensed its adalimumab biosimilar Handayuan to Getz Pharma Pvt. Ltd. and its affiliated company Getz Pharma International FZ LLC in an $8 million deal.
LONDON – Antibody-drug conjugate specialist Heidelberg Pharma AG has secured a route into Asia and a fresh injection of much-needed capital, in a licensing and equity deal with Huadong Medicine Co. Ltd. worth up to €930 million (US$1.1 billion).
SK Bioscience Ltd. is developing a vaccine intended to simultaneously immunize people against the flu and COVID-19. It is the first vaccine of its type to be developed in South Korea and will use the technology from Skycellflu, a cell-cultivated influenza vaccine developed by the Seongnam-si, South Korea-based company.
Huadong Medicine Co. Ltd.’s wholly owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has acquired Asia-Pacific rights to two drugs from Kiniksa Pharmaceuticals Ltd. in a deal worth up to $662 million. “This collaboration aims to bring Kiniksa’s therapeutics to patients in the Asia Pacific Region suffering from severe autoimmune and inflammatory diseases,” said Sanj Patel, chairman and CEO of Kiniksa. “The collaboration also provides nondilutive capital, cost-sharing, and resources for clinical trials to accelerate our drug development and commercialization efforts.”
Japan’s Ministry of Health, Labor and Welfare (MHLW) released a number of new guidelines and clarifications on medical device regulatory issues including cybersecurity, remanufactured single-use devices (SUDs) and the Medical Device Single Audit Program (MDSAP).
Biorchestra Co. Ltd. has raised ￦54 billion ($45.1 million) in its latest series C fundraising, which will boost the development of the company’s lead RNA-based candidate for treating neurodegenerative diseases. BMD-001 is Daejeon, South Korea-based Biorchestra’s antisense oligonucleotide candidate for treating Alzheimer’s disease.
On the success of last year’s establishment of a global mRNA vaccine technology transfer hub in South Africa, the World Health Organization (WHO) announced its next step Feb. 23: the creation of a global biomanufacturing training hub in South Korea that will serve low- and middle-income countries wanting to produce biologics, such as vaccines, insulin, monoclonal antibodies and cancer treatments.
RSS
